Form 4: Structure Therapeutics CMO Sells Shares for Tax

Structure Therapeutics' Chief Medical Officer, Blas Coll Crespo, disposed of 8,106 ordinary shares to cover tax obligations related to a restricted share unit award vesting.

Summary

• Blas Coll Crespo, Chief Medical Officer of Structure Therapeutics Inc. (GPCR), reported a transaction on September 18, 2025.
• A total of 8,106 ordinary shares were disposed of by the reporting person.
• These shares were withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.
• The disposition occurred at a price of $7.7433 per share.
• Following this transaction, Coll Crespo beneficially owns 216,807 ordinary shares.
• Ordinary Shares of the Issuer may be represented by American Depositary Shares (ADSs), with each ADS representing three Ordinary Shares.

Sentiment

Score: 6

Explanation: The transaction represents a routine disposition of shares to cover tax obligations upon the vesting of a restricted share unit award, which is a common compensation event for executives. It is not a discretionary sale, indicating a neutral to slightly positive event as it signifies compensation realization.

Positives

• The transaction indicates the vesting of a restricted share unit award, which is a form of compensation realization for the Chief Medical Officer.

Negatives

• A reduction of 8,106 ordinary shares from the Chief Medical Officer's direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The transaction represents a routine compensation event for an executive, with a minor reduction in direct insider ownership due to tax withholding, which is generally not considered a significant impact.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary disposition of shares by the Chief Medical Officer to satisfy tax obligations upon the vesting of a restricted share unit award. Such transactions are common and do not typically signal a change in company fundamentals or management's outlook, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Structure Therapeutics, GPCR, Form 4, insider transaction, share disposition, Chief Medical Officer, RSU, tax withholding